Why Mylan? Because our passion, innovation and commitment drive us to set new standards in health care. Seeing is believing.
Investors 1
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
Mentions in press and media 5
| Date | Title | Description |
| 15.07.2026 | LumaCina Appoints Gary Bird as CEO to Accelerate Growth and Expand Global Sterile Injectables Portfolio | Executive Chair Mark Crotty to continue guiding long-term strategic direction PERTH, Australia, July 15, 2026 /PRNewswire/ -- LumaCina, a global supplier and marketer of sterile injectable pharmaceutical products and a Bridgewest Group port... |
| 30.08.2013 | Meda Acquires Acton Pharmaceuticals for $135M | Meda (STO:MEDAA), a Swedish pharmaceutical company, acquired Acton Pharmaceuticals, a Marlborough, Mass.-based pharmaceutical company focused on treating respiratory conditions, for $135m. In addition to the purchase price, the acquisition ... |
| 21.05.2012 | BDSI’s cancer pain product preps for Europe, triggers $2.5M milestone | The U.S. Food and Drug Administration approved Onsolis in 2009, though the product has experienced slow U.S. sales since. The FDA put the product under a Risk Evaluation and Mitigation Strategy, or REMS, which imposes stricter requirements ... |
| 20.07.2007 | Sweden’s Meda acquires specialty pharma MedPointe for $820M | Meda, a Swedish specialty-pharmaceutical company, agreed to acquire MedPointe, another specialty pharma in Somerset, N.J., for roughly $820 million in cash and stock. Meda’s release — and be careful, as it’s a little difficult to slog throu... |
| - | BDSI’s cancer pain product preps for Europe, triggers $2.5M milestone | The breakthrough cancer pain treatment developed by BioDelivery Sciences (NASDAQ:BDSI) International is making progress toward entering the European market, triggering a $2.5 milestone payment from BDSI’s drug partner Meda Pharmaceuticals. ... |